Regardless of prior treatment , all patients in this study received subcutaneous @-mg tabalumab Q@W for the first @months , then a one-time increase to @-mg tabalumab Q@W ( @-mg/@-mg group ) and a one-time decrease to @-mg tabalumab Q@W per patient was allowed ( @-mg/@-mg/@-mg group ) .